Diabetes Care Review Time

ADA's official author pages are strong on article requirements, clinical-trial reporting, and submission mechanics. What they do not do is publish a clean live public dashboard with stage-by-stage medians.

That is where practical planning data become useful. The surrounding journal research in this repo repeatedly points to a workflow with:

• a quick desk and technical screen
• a longer editorial evaluation stage
• then a more familiar peer-review cycle

That model matches the journal's editorial identity. Diabetes Care is trying to decide whether the paper actually changes diabetes management, outcomes, prevention, or implementation. That takes longer than checking syntax or sending a file out immediately.

That is why Diabetes Care feels slower than many authors expect. The journal is not simply sending files out quickly and letting reviewers sort them. It is doing a large amount of selection internally first.

The central editorial question at Diabetes Care is unusually specific: is the manuscript fundamentally about diabetes care, or is diabetes only the population in which the study happened?

That makes the pre-review stage weighty. Editors can spend time on manuscripts that are:

• clinically polished but not actually diabetes-care centered
• statistically sound but too small for meaningful clinical endpoints
• mechanistically interesting but weak on human validation
• relevant to metabolism or endocrinology broadly without enough diabetes-management consequence
• hard to generalize beyond one narrow practice setting or population

So the longer timeline is not random delay. It is the journal protecting a strong clinical identity.

The common causes are:

• diabetes is the setting rather than the actual clinical problem
• endpoints are statistically significant but not clinically meaningful
• the cohort is too narrow to support practice-wide conclusions
• the paper leans on surrogate or mechanistic logic without enough human outcome relevance
• reviewer and editor concern that the work belongs in Diabetes, Diabetologia, or another related journal instead

When Diabetes Care gets slower, it is often because the manuscript is close enough to debate but not yet obvious enough to move cleanly.

Diabetes Care is up from 14.8 in 2023 to 16.6 in 2024, which reinforces that the journal remains one of the most visible homes for clinical diabetes work. The combination of a high Impact Factor, strong 5-year JIF, and high SJR means the journal does not need to compromise on scope to stay busy.

For review time, that usually translates into a stronger internal editorial screen. The journal can take time deciding whether the paper really deserves its audience.

Even strong planning data hide several things:

• some papers die in under two weeks, which can make community medians hard to interpret
• the editorial review stage is often doing more work than the reviewers
• a first decision at 110 days can still be a major-revision outcome rather than a near-accept
• timing does not tell you whether the endpoint choice was clinically persuasive enough

So review speed matters, but editorial fit matters more.

In our pre-submission review work, the biggest timing mistake is assuming that "diabetes-related" is good enough. Diabetes Care usually wants something stricter: a paper that clearly changes diabetes prevention, treatment, monitoring, outcomes, or care delivery.

The manuscripts that move best through the journal usually have:

• diabetes as the actual clinical problem being solved
• clinically meaningful endpoints, not only statistically positive ones
• a cohort and design large enough for the central claim
• enough generalizability that readers can imagine using the result in practice

That combination tends to justify the long review path. Without it, the journal's slower process becomes mostly expensive waiting.

For Diabetes Care, timing matters less than clinical diabetes specificity. The better question is whether the manuscript already behaves like a Diabetes Care paper.

That is why the better next reads are:

• Diabetes Care journal profile
• Diabetes Care submission guide
• Diabetes Care impact factor
• Diabetes Care acceptance rate

A Diabetes Care clinical-fit check is usually more useful than trying to optimize around the median alone.

Diabetes Care review time is best understood as a long editorial pathway attached to a selective clinical-diabetes filter. If the manuscript is truly about improving diabetes care, the process can be worth the wait. If not, the long timeline mostly delays the inevitable journal decision.